Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: An analysis of the ASSOCIATE study

International Journal of Cardiology

Volumn 168, Issue 2, 2013, Pages 789-794

  Tardif, Jean Claude ^a   Ponikowski, Piotr ^b,c   Kahan, Thomas ^d  

^a MONTREAL HEART INSTITUTE   (Canada)

^b MILITARY HOSPITAL   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d DANDERYD HOSPITAL   (Sweden)

Author keywords

Beta blocker; Heart rate; Ivabradine; Stable angina pectoris

Indexed keywords

ATENOLOL; IVABRADINE; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EXERCISE INTENSITY; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTING HEART RATE; SINUS BRADYCARDIA; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS;

BETA-BLOCKER; HEART RATE; IVABRADINE; STABLE ANGINA PECTORIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGINA, STABLE; ATENOLOL; BENZAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84885304142     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.10.011     Document Type: Article

References (24)

1. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med 2005;352: 1951-8.
2. Panza JA, Diodati JG, Callahan TS, Epstein SE, Quyyumi AA. Role of increases in heart rate in determining the occurrence and frequency of myocardial ischemia during daily life in patients with stable coronary artery disease. J Am Coll Cardiol 1992;20:1092-8.
3. Kop WJ, Verdino RJ, Gottdiener JS, O'Leary ST, Bairey Merz CN, Krantz DS. Changes in heart rate and heart rate variability before ambulatory ischemic events(1). J Am Coll Cardiol 2001;38:742-9.
4. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity. Circadian distribution and response to anti-ischemic medication. The Angina and Silent Ischemia Study Group (ASIS). Circulation 1993; 88:92-100.
5. GibbonsRJ, Abrams J, Chatterjee K, et al. ACC/AHA2002 guideline update for themanagement of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on theManagement of PatientsWith Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-68.
6. DiFrancesco D, Camm AJ. Heart rate lowering by specific and selective If current inhibition with ivabradine. A new therapeutic perspective in cardiovascular disease. Drugs 2004;64:1757-65.
7. Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-23.
8. Ruzyllo W, Tendera M, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 2007;67:393-405.
9. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36.
10. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337-45.
11. Tardif JC, Ponikowski P, Kahan T. Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4 month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540-8.
12. Bohm M, Swedberg K, Komajda M, et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010;376:886-94.
13. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16.
14. Bois P, Bescond J, Renaudon B, Lenfant J. Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells. Br J Pharmacol 1996;118: 1051-7.
15. Borer JS, Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther 2008;15:461-73.
16. Daly C, Clemens F, Lopez-Sendon J, et al. Inadequate control of heart rate in patients with stable angina: results from the European Heart Survey. Postgrad Med J 2010;86:212-7.
17. Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One 2012;7:e36284.
18. Fox K, GarciaMA, Ardissino D, et al. Guidelines on themanagement of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
19. Amosova E, Andrejev E, Zaderey I, Rudenko U, Ceconi C, Ferrari R. Efficacy of ivabradine in combination with beta-blocker versus uptitration of beta-blocker in patients with stable angina. Cardiovasc Drugs Ther 2011;25:531-7.
20. Savelieva I, Camm AJ. I(f) inhibition with ivabradine : electrophysiological effects and safety. Drug Saf 2008;31:95-107.
21. Tendera M, Talajic M, Robertson M, et al. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy). Am J Cardiol 2011;107:805-11.
22. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
23. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006;27:1153-8.
24. Tardif JC, Ponikowski P, Kahan T. Ivabradine improves exercise capacity in patients with stable angina pectoris receiving maximal tolerated dose of betablockers: a subgroups analysis of the ASSOCIATE study. P1335. Eur Heart J 2010; 31(Suppl. 1):198-9.